Premium
Regression of cardiac hypertrophy in cyp1a1 ren‐2 transgenic rats
Author(s) -
Peters Barbara S.,
Dornaika Rami,
Hosten Norbert,
Hadlich Stefan,
Mullins John J.,
Peters Jörg,
Rettig Rainer
Publication year - 2012
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.23661
Subject(s) - cardiac hypertrophy , muscle hypertrophy , medicine , transgene , cardiology , regression , genetically modified mouse , biology , pathology , statistics , mathematics , biochemistry , gene
Purpose: To evaluate the usefulness of the cyp1a1 ren‐2 transgenic rat model of inducible hypertension for studies of the development and regression of cardiac hypertrophy. Materials and Methods: Cyp1a1 ren‐2 rats received a diet containing 0% or 0.167% indole‐3‐carbinonl (I3C) for 4 weeks to induce hypertension. Cardiac magnetic resonance imaging (MRI) at 7 T was performed every second week for 10 weeks to measure left ventricular mass and the ejection fraction. Concomitantly, in six cyp1a1 ren‐2 rats blood pressure was recorded telemetrically. Results: Plasma prorenin concentrations rose from 138 ± 38 to 15,490 ± 3990 ng/angiotensin I/mL/h ( P < 0.001) in I3C‐treated transgenic rats and returned to basal levels after cessation of I3C. Mean blood pressure increased to a plateau of 169 ± 11 mmHg by the second week of induction. After cessation of I3C (day 28), arterial pressure dropped to values slightly below those prior to induction within 4 days (basal: 106 ± 7 mmHg, day 32: 103 ± 21 mmHg; NS). At day 28, left ventricular mass was increased by 39% vs. 4% in controls ( P < 0.001) without changes of the ejection fraction. Cardiac hypertrophy was completely reversed at day 70, as evaluated by MRI. Conclusion: The cyp1a1 ren‐2 transgenic rat is a useful model to study reversal and healing in the absence of surgical interventions. J. Magn. Reson. Imaging 2012;36:373–378. © 2012 Wiley Periodicals, Inc.